Abstract
Public SARS-CoV-2 genomes from the Delta lineage show complex and confusing patterns of mutations at Spike codon 142, and at another nearby position, Spike codon 95. It has been hypothesised that these represent recurrent mutations with interesting evolutionary dynamics, and that these mutations may affect viral load. Here we show that these patterns, and the relationship with viral load, are artifacts of sequencing difficulties in this region of the Delta genome caused by a deletion in the binding site for the 72_RIGHT primer of the ARTIC V3 schema. Spike G142D should be considered a lineage-defining mutation of Delta.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by COG-UK, supported by funding from the Medical Research Council (MRC) part of UK Research and Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute This research was funded in whole or in part by the Wellcome Trust [210918/Z/18/Z.].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was done as part of surveillance for COVID-19 under the auspices of Section 251 of the National Health Service Act 2006. It therefore did not require individual patient consent or ethical approval. The COVID-19 Genomics UK (COG-UK) study protocol was approved by the Public Health England Research Ethics Governance Group.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Adds reference to newly-released Virological post on non-specific amplification.
Data Availability
We analyse three datasets here: Viral genomes sequenced by the Sanger Institute at part of the COG-UK Consortium. These can be accessed at https://cog-uk.s3.climb.ac.uk/phylogenetics/latest/cog_all.fasta, or as an alignment at https://cog-uk.s3.climb.ac.uk/phylogenetics/latest/cog_alignment.fasta. Metadata, including lineage calls, is at https://cog-uk.s3.climb.ac.uk/phylogenetics/latest/cog_metadata.csv. Global SARS-CoV-2 genomes available at https://gisaid.org. An alignment is also available there within the Downloads section, with a separate metadata file, including lineage calls. Raw reads from the Sequence Read Archive were accessed from https://www.ncbi.nlm.nih.gov/sra Fully deidentified Ct-genotype mappings, as well as the other COG-UK data analysed are available at https://github.com/theosanderson/amplicon_72.
